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Carboplatin is a derivative of cisplatin; it has a similar mechanism of action, but differs in terms of 
structure and toxicity. It was approved by the FDA in the 1980s and since then it has been widely used 
in the treatment of several tumor types. This agent is characterized by its ability to generate lesions in 
DNA through the formation of adducts with platinum, thereby inhibiting replication and transcription and 
leading to cell death. However, its use can lead to serious inconvenience arising from the development of 
resistance that some patients acquire during treatment, limiting the scope of its full potential. Currently, 
the biochemical mechanisms related to resistance are not precisely known. Therefore, knowledge of 
pathways associated with resistance caused by carboplatin exposure may provide valuable clues for 
more efficient rational drug design in platinum-based therapy and the development of new therapeutic 
strategies. In this narrative review, we discuss some of the known mechanisms of resistance to platinum-
based drugs, especially carboplatin.
Uniterms: Carboplatin/mechanisms of resistance. Cisplatin/mechanisms of resistance. Drugs/resistance. 
Molecular targets. Antitumors/platinum-based.
A carboplatina é um derivado da cisplatina, possuindo mecanismo de ação similar, diferindo em 
estrutura e toxicidade. Este fármaco foi aprovado pelo FDA em meados de 1980 e, desde então, tem 
sido amplamente usado no tratamento de diversos tipos de tumores. Este agente é caracterizado por sua 
habilidade em gerar lesões no DNA através da formação de adutos com a platina, inibindo a replicação e a 
transcrição, levando à morte celular. Entretanto, seu uso pode levar a graves inconvenientes, advindos do 
desenvolvimento de resistência que alguns pacientes adquirem durante o tratamento, limitando o alcance 
de seu potencial. Até então, os mecanismos bioquímicos relacionados ao problema da resistência não são 
precisamente conhecidos. Dessa forma, o conhecimento das vias associadas à resistência causada pela 
exposição à carboplatina pode prover valiosas informações para o planejamento racional de fármacos 
com base em platina mais eficiente e para o desenvolvimento de novas estratégias terapêuticas. Nesta 
revisão narrativa, serão discutidos alguns mecanismos de resistência a fármacos com base em platina, 
especialmente ao antitumoral carboplatina.
Unitermos: Carboplatina/mecanismos de resistência. Cisplatina/mecanismos de resistência. Fármacos/
resistência. Alvos moleculares. Antitumorais/baseados em platina.
INTRODUCTION
Carboplatin is a derivative of cisplatin and has a 
similar mechanism of action, differing only in terms of 
structure and toxicity. The anticancer activity of cisplatin 
was discovered in the early 1960s by Professor Barnett 
Rosenberg at the University of Michigan (Rosenberg, 
Vancamp, Krigas, 1965; Rosenberg et al., 1969). He 
was interested in studying the effects of electric fields on 
bacterial growth, by establishing their involvement in the 
process of cell division. It was noted that after applying 
an electric field through a set of platinum electrodes 
immersed in a solution containing Escherichia coli, the 
cells not divided in a normal manner, and demonstrated 
filamentous growth of up to 300 times above normal 
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(Rosenberg, Vancamp, 1970). This effect was found to be 
unrelated to the electric field, but related to the products 
of electrolysis of the platinum electrodes. Subsequent 
detailed chemical analysis identified several platinum 
complexes which induce this behavior, and that while 
the bivalent complex cis-[Pt (NH3)2Cl2] was active, the 
trans isomer was much less active (Rosenberg, Vancamp, 
Krigas, 1965; Jamieson, Lippard, 1999).
After testing bacteria, Rosenberg started working 
on the possibility of using cisplatin in cancer treatment 
due to its anti-proliferative ability. Initial tests were 
performed on mice with malignant tumors, such 
as Kaposi 180. After the application of appropriate 
amounts of cisplatin, it was found that the drug was an 
effective antitumor agent, but at higher doses, cisplatin 
produced side effects such as kidney damage, discomfort, 
dizziness, nausea, and vomiting (Carozzi et al., 2009). 
According to Choudhary, Sood and Wang (2013), this 
drug has been proven to be effective for medical use in 
the treatment of several human cancers, including testis, 
ovary, brain, bladder, and lung.
After the pioneering work of Rosenberg, a huge 
number of metal complexes were studied, most of 
which were platinum-based. Since 1979, 1,055 platinum 
compounds have been tested, of which 185 were active. 
Considerable research worldwide has been triggered 
and more than 3,000 analogous compounds have been 
synthesized. Some of these new compounds are less toxic 
than cisplatin, but only five other compounds have been 
approved for commercialization: oxaliplatin, nedaplatin, 
lobaplatin, heptaplatin (the marketing of latter three is 
restricted to Japan, China and Korea, respectively), and 
carboplatin (McWhinney, Goldberg, McLeod, 2009; 
Wheate et al., 2010).
Carboplatin (1,1-cyclobutyldicarboxylate) is one 
of the main platinum-based drug used as an antitumor 
drug. It is intended specifically for the treatment of 
cancer of the testis, ovary, head, neck, and small cell lung 
cancer (Fuertes, Alonso, Perez, 2003). The main target of 
carboplatin is DNA, to which it binds efficiently, thereby 
inhibiting replication and transcription and inducing cell 
death (Brabec, Kasparkova, 2005). The nature of these 
DNA adducts affects a number of transduction pathways 
and triggers apoptosis or necrosis in tumor cells. The 
adducts formed by this compound can be monoadducts 
or intra and interchain diadducts (Hah et al., 2006) 
(Figure 1).
The development of resistance to platinum-based 
chemotherapy is a major clinical challenge in cancer 
treatment, since the cellular response which confers 
resistance to carboplatin is multifactorial and poorly 
understood (Wernyj, Morin, 2004; Shahzad, Berestein, 
Sood, 2009). It has been observed that the intracellular 
mechanisms by which cells become resistant to carboplatin 
include increased drug detoxification by the thiol groups 
in metallothionein and glutathione, repair, and improved 
tolerance to nuclear damage, leading to a concomitant 
reduction in apoptosis and reduced accumulation of 
intracellular carboplatin (Wang, Lippard, 2005; Stewart, 
2007). Thus, inducing greater damage to DNA, impairing 
mechanisms of DNA repair, or activating and preventing 
apoptosis may lead to decreased tumor cell viability and 
could overcome resistance (Shahzad, Berestein, Sood, 
2009; Burger et al., 2011).
Because of the low toxicity of carboplatin in 
clinical treatment, its association with other antitumor 
drugs has been tested in different types of cancer. 
Table I shows some of these associations and clinical 
outcomes in order to examine whether the combination 
therapy is favorable or not to the patient and which 
types of tumors (Kang et al., 2006; Honing et al., 2014; 
Chang et al., 2014; Angioli et al., 2013; Strauss et al., 2008; 
FIGURE 1 - Formation of adducts between DNA and carboplatin.
Carboplatin: molecular mechanisms of action associated with chemoresistance 695
TABLE I - Combination therapy with carboplatin
Combination therapy Dosage Tumor Favorable References
Carboplatin/Paclitaxel AUC 5 e 175 mg/m2 Epithelial Ovarian 
Cancer
Yes Kang et al. (2006)
Carboplatin/Paclitaxel AUC 2 e 50 mg/m2 Cancer of Esophagus Yes Honing et al.(2014)
Carboplatin/Paclitaxel AUC 5,5 e 175 mg/m2 Lung Cancer Yes, in stage IB patients who 
have tumors ≥ 4.0 cm
Chang et al. (2014)
Carboplatin/Paclitaxel AUC 6 e 175 mg/m2 Cancer of the Cervix Yes Angioli et al. (2013)
Carboplatin/Paclitaxel AUC 6 e 200 mg/m2 Lung Cancer Yes, in stage IB patients who 
have tumors ≥ 4.0 cm
Strauss et al.(2008)
Carboplatin/Paclitaxel AUC 1 e 40 mg/m2 Cancer of the head and 
neck
Yes Semrau et al. (2011)
Carboplatin/Docetaxel AUC 6 e 60 mg/m2 Cancer of the Cervix No Ukita et al.(2013)
Carboplatin/Docetaxel AUC 6 e 75mg/m2 Breast Cancer Yes, in patients with 
metastatic breast cancer
Perez et al.(2005)
Carboplatin/Docetaxel AUC 5,5 e 75mg/m2 Lung Cancer Yes Zhi et al.(2013)
Carbopltin/Gemcitabine AUC 5 e 1000 mg/m2 Lung Cancer Yes Lim et al. (2013)
Carboplatin/Pemetrexed AUC 5 e 500 mg/m2 Lung Cancer Yes Pereira et al.(2011)
Carboplatin/Paclitaxel + 
Bevacizumab
AUC 6, 200 mg/m2 e 
15mg/kg
Lung Cancer Yes Twelves et al. (2014)
Carboplatin/Vinorelbine AUC 2,5 e 25mg/m2 Lung Cancer Yes Masters et al. (2003)
AUC, area under the concentration-time curve 
Semrau et al., 2011; Ukita et al., 2013; Perez et al., 2005; 
Zhi et al., 2013; Lim, Li, Song, 2013; Pereira et al., 2011; 
Twelves et al., 2014; Masters et al., 2003).
The aim of this narrative review was to discuss 
some of the known molecular mechanisms involved in the 
absorption, metabolism, detoxification, and resistance to 
platinum-based drugs, especially carboplatin.
MECHANISM OF ACTION
To be activated, carboplatin must cross the cell 
membrane. Inside the cell, the molecule undergoes 
hydrolysis of 1,1-cyclobutanedicarboxylate, becoming 
positively charged. This allows carboplatin to interact 
with nucleophilic molecules (Figure 2) within the 
cell, including DNA, RNA and protein, generating 
the formation of adducts of platinum (McWhinney, 
Goldberg, McLeod, 2009). This process occurs through 
covalent binding of carboplatin to the N7 site of purine 
bases, forming DNA-protein or DNA-DNA interactions 
(Eastman, 1987; Amptoulach, Tsavaris, 2011).
Due to the pharmacodynamics of carboplatin, it has 
fewer side effects than its precursor cisplatin, although 
less potency, which might be due to differences in rates 
of adduct formation with DNA. These toxicity differences 
are probably due to the low reactivity rate of carboplatin 
with nucleophiles, since 1,1-cyclobutanedicarboxylate is 
a poorer leaving group than chloride (Figure 3) (Hah et 
al., 2006). 
The linkage between DNA and carboplatin can 
produce lesions in DNA. Crosslinking between strands of 
DNA (interstrand cross-linking; ISC) is the most cytotoxic 
effect, because it inhibits the process of DNA replication, 
FIGURE 2 - Hydrolysis of carboplatin inside the cell. Ctr1 is the 
high affinity copper transporter (further described in Figure 4).
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causing changes that generate errors in replication, with 
the accumulation of cells in G2/M phase and the induction 
of apoptosis (Shi et al., 1994)1994. Alkylation of a single 
strand of DNA can be repaired easily, but cross-linked 
inter strands such as those produced by bifunctional 
alkylating agents require more complex mechanisms of 
repair (Rabik, Dolan, 2007).
Inside the cell, recognition of the damage caused 
by platinum occurs through the repair machinery. In 
the context of chromatin, the repair system may require 
exposure of the damaged double-stranded DNA outwards 
from the nucleosome, which is the fundamental building 
block of chromatin. It is the configuration of the DNA 
rotation on the surface of histone octamer which defines 
nucleotides that are directed into the solvent and which are 
occluded by histones (Kornberg, Lorch, 1999). Therefore, 
determining the connections between platinum in the DNA 
are located within the nucleosome is an important step 
in understanding the process of cell recognition. A key 
question is whether the adduct of platinum or the DNA 
sequence determines the configuration of the rotation of a 
DNA segment into the nucleosome and therefore how the 
platinum lesion is presented to the replication machinery, 
thereby affecting transcription and repair of the cell 
(Danford et al., 2005).
The system of DNA mismatch repair (MMR) is 
an important mechanism of replication which avoids 
errors caused by mutations (Fink et al., 1996). MMR 
is based on the recognition of DNA distortion caused 
by the presence of 6-thioguanine and adducts produced 
by carboplatin, generating an injury signal which might 
contribute to the initiation of apoptosis. This mechanism 
suggests that MMR proteins serve to detect DNA damage 
caused by these agents (Rabik, Dolan, 2007). Therefore, 
the loss of this repair mechanism can cause carboplatin 
resistance due to the inability to recognize the complex 
formed by DNA adducts with platinum drugs (Fink et al., 
1996). Some studies have provided evidence that the loss 
of MMR proteins is associated with drug resistance in 
ovarian tumors. Additionally, methylation in the MLH1 
promoter (the regulatory part of one MMR gene) performs 
FIGURE 3 - Molecular structure of platinum-based drugs. The 












an important role in the resistance to cisplatin in ovarian 
cancer cells grown in vitro (Zeller et al., 2012; Xiao, 
Melton, Gourley, 2014). Nucleotide excision repair (NER) 
is highly conserved and plays a key role in mediating 
resistance to drugs based on platinum (Rabik, Dolan, 
2007). Injuries that result in changes to the helical structure 
of DNA and interfere with the mechanism of replication 
and transcription are repaired by this route. One important 
protein in the repair pathway of nucleotide excision repair 
is cross-complementation group 1 (ERCC1), which is 
postulated to play an important role in the efficacy of the 
drug (McWhinney, Goldberg, McLeod, 2009).
The repair of caudate adducts by platinum agents 
mainly occurs through the NER pathway. Although 
all three types of intra-strand crosslinks (1,2-d (ApG), 
1.2-d (GPG) and d-1.3 (GpNpG)) are recognized by the 
NER mechanism, the first two intra-chain crosslinks are 
repaired less efficiently than 1.3 intra-chain crosslinks, 
supporting the hypothesis that 1.2 intra-strand crosslinks 
in DNA cause cytotoxic lesions (Rabik, Dolan, 2007). 
Two important molecules involved in the synthesis and 
damage repair of DNA, ERCC1 and RRM1, have been 
associated with the efficacy of treatment with platinum-
based drugs. According to the work of Selvakumaran et 
al. (2003), ovarian cancer cell lines known to be resistant 
to platinum compounds show increased sensitivity after 
the silencing of ERCC1 protein expression using RNA 
interference, thereby demonstrating the association 
between NER and the clinical outcome of chemotherapy. 
Furthermore, studies evaluating the mRNA levels of 
ERCC1 in tumors from patients in clinical trials of non-
small cell lung (Lord et al., 2002), colorectal (Shirota 
et al., 2001), and ovarian cancers (Kang et al., 2006) 
also showed an inverse association with survival or 
response to platinum compounds (Reynolds et al., 2009; 
Bowden, 2014; Moxley et al., 2013; Vilmar, Sørensen, 
2009). Lower ERCC1 expression, evaluated based on 
mRNA expression or protein levels, is related to better 
outcomes in several cancers after platinum-based 
treatment (De Castro et al., 2011). Da Costa Miranda et 
al. (2014) evaluated the prognostic and predictive role of 
the immunohistochemical expression of ERCC1 on the 
tumor response in patients with advanced biliary tract 
cancer. According to these authors, this expression was 
not either predictive or prognotic. However, the authors 
cite some drawbacks of the study, as the sample group 
was small and the study was conducted in a single center 
in Brazil. The manner whereby platinum drugs enter 
cells has traditionally been attributed to simple passive 
diffusion. However, some studies suggest that a number of 
mechanisms of uptake and efflux are active in the process, 
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and altered regulation of these transporters is responsible 
for the reduced accumulation of drugs in resistant cells 
(Hall et al., 2008). Anticancer drugs based on platinum, 
such as cisplatin, oxaliplatin and carboplatin, are captured 
by cells, followed by binding to DNA and cytotoxicity 
(Wang, Lippard, 2005). Platinum uptake varies widely 
among different cell types and different types of tissues, 
and is a factor in the sensitivity and resistance of tumors 
(Liu et al., 2013).
Transporters of metals such as copper transporters, 
i.e. CTR1, ATP7A and ATP7B, have been of particular 
interest in the study of drugs based on platinum. A 
significant influence of the carrier CTR1 has been observed 
in mediating the influx of carboplatin, while ATP7B and 
ATP7A are known to be mediators of copper removal 
from the cell. ATP7A is expressed in the epithelium of 
the intestine and other tissues, except the liver, whereas 
ATP7B is expressed in liver, kidney, and to a lesser extent 
in the brain (Sprowl, Ness, Sparreboom, 2013). The 
ATP7B transporter, an ATP-binding cassette, sub-family 
C2 (ABCC2, also known as MRP2 or cMOAT) has been 
reported to be important in the efflux of carboplatin (Cui 
et al., 1999; Katano et al., 2003; Samimi et al., 2004b). 
The uptake and efflux of carboplatin are apparently linked 
to the metabolism of copper; this pathway leads to the 
hypothesis that copper and carboplatin can interfere with 
their mutual transport, thereby reducing the absorption of 
each other (Ohashi et al., 2003). One of the main efflux 
pathways associated with copper, and apparently also 
associated with carboplatin efflux, is the detoxification 
mechanism mediated by glutathione and metallothionein 
(Figure 4).
According to McWhinney, Goldberg and McLeod 
(2009), the exclusion of the CTR1 gene in yeast results 
in a significant accumulation of three clinically available 
platinum analogs, including carboplatin. Forced 
overexpression of CTR1 in human ovarian cancer cells 
increases the absorption of platinum-based drugs, 
indicating that CTR1 plays a key role in the cellular 
accumulation of these drugs.
Studies in patients with Menkes disease, or 
in patients that express neither ATP7A nor ATP7B, 
demonstrated greater accumulation of copper than cells 
transfected with vectors containing ATP7A or ATP7B 
(Samimi et al., 2004a), indicating that these carriers have 
higher levels of expression in platinum-resistant cells 
(Katano et al., 2003). Furthermore, high levels of ATP7A 
and ATP7B are associated with a poor response in patients 
with ovarian cancer receiving cisplatin or carboplatin-
based chemotherapies (Martinez-Balibrea et al., 2009). 
Li et al. (2012) demonstrated that overexpression ATP7A 
in non-small cell lung cancer cells conferred resistance to 
platinum-based chemotherapy.
CONCLUSION
Resistance to carboplatin is a major problem 
in cancer therapy and has attracted the attention of 
researchers. Hopefully, further investigations will be 
carried out so that we can identify the causal mechanisms 
of resistance to carboplatin, allowing more effective use 
of this highly effective product. The DNA repair pathway 
increases cell resistance to carboplatin, and activation of 
the NER or MMR pathway in addition to the detoxification 
mechanisms of carboplatin (cytoplasmic mechanisms) 
are known to be involved in resistance. New observations 
have pointed to metal transporters as a mechanism of 
resistance to carboplatin, including the copper transporters 
CTR1, ATP7A and ATP7B. Determining the causative 
mechanism of resistance to platinum agents in tumors and 
reducing the toxic side effects of these drugs in patients 
will be beneficial to a large number of cancer patients who 
receive these drugs.
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FIGURE 4 - Mechanism of detoxification of carboplatin within 
the cell.
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